{"id":"NCT03350620","sponsor":"Vyluma, Inc.","briefTitle":"CHAMP: Study of NVK-002 in Children With Myopia","officialTitle":"A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children With Myopia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-20","primaryCompletion":"2022-09-07","completion":"2023-10-19","firstPosted":"2017-11-22","resultsPosted":"2024-11-27","lastUpdate":"2024-11-27"},"enrollment":670,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Myopia"],"interventions":[{"type":"DRUG","name":"NVK-002 Concentration 1","otherNames":["NVK-002 Conc 1"]},{"type":"DRUG","name":"NVK-002 Concentration 2","otherNames":["NVK-002 Conc 2"]},{"type":"DRUG","name":"Placebo","otherNames":["Vehicle"]}],"arms":[{"label":"NVK-002 Concentration 1","type":"EXPERIMENTAL"},{"label":"NVK-002 Concentration 2","type":"EXPERIMENTAL"},{"label":"Vehicle (Placebo)","type":"PLACEBO_COMPARATOR"}],"summary":"Stage 1: To evaluate the safety and efficacy of 2 concentrations of NVK-002 compared to Vehicle (placebo) for slowing the progression of myopia in children over a 3 year treatment period.\n\nStage 2: To observe safety and efficacy in subjects re-randomized to one (1) year of treatment with NVK-002 or Vehicle following 3 years of treatment in children with progressive myopia.","primaryOutcome":{"measure":"Number of Subjects' Eyes That Show < 0.50 D Myopia Progression (SER, Spherical Equivalent Refraction) at the Month 36 Visit","timeFrame":"36 Months","effectByArm":[{"arm":"NVK-002 Concentration 1","deltaMin":79,"sd":null},{"arm":"NVK-002 Concentration 2","deltaMin":106,"sd":null},{"arm":"Vehicle (Placebo)","deltaMin":61,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":26,"countries":["United States","Hungary","Ireland","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["37261839"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":164},"commonTop":["nasopharyngitis","COVID-19","headache","seasonal allergy","pyrexia"]}}